ALSO IN THIS MONTH'S ISSUE

  • Rx Industry Under Multifront Siege
    Rx Industry Under Multifront Siege

    The latest regulatory salvo from the Trump administration on Medicare Part D and the Democratic takeover of the House of Representatives has the pharmaceutical industry scrambling to fight a multifront war to defend market-based pricing in the United States.

  • What Does The Future Hold?
    What Does The Future Hold?

    Chief editor, Rob Wright, discusses some forward-looking sessions from the annual CNS Summit, along with what to expect in Life Science Leader’s annual outlook issue.

  • A Look At 2018’s CDMO Expansions
    A Look At 2018’s CDMO Expansions

    ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

  • Talented People Must Choose To Do Great Work: Curate A Culture
    Talented People Must Choose To Do Great Work: Curate A Culture

    The fate of your business rests largely on the willingness of individuals to choose to invest their best discretionary effort in your company’s cause — to dig deep for innovative ideas, to imagine solutions outside any box, to perceive subtle shifts and faint signals.

  • What Supply Chain Trends Are You Paying Closest Attention To?
    What Supply Chain Trends Are You Paying Closest Attention To?

    See the answer from Anu Hans, VP of strategic initiatives at Janssen Supply Chain.

More from this month's issue

BEYOND THE PRINTED PAGE

  • Making A Difference Matters

    Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.

  • Helen Torley’s Path To The C-Suite

    Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.

  • Could Halozyme’s U.S. Patent 8,846,034 Be Another Royalty Boon?

    Helen Torley, president and CEO of Halozyme Therapeutics, discusses hyaluronan and the role it plays in development of ENHANZE, PEGPH20 along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).

More beyond the printed page articles

 EVENTS

Bio CEO & Investor Conference February 11 - 12, 2019
New York, NY
BIO Asia International Conference March 5 - 6, 2019
Tokyo
26th International Molecular Medicine Tri-Conference March 10 - 15, 2019
San Francisco, CA
INTERPHEX April 2 - 4, 2019
New York, NY
20th Annual Computer and IT Systems Validation April 23 - 25, 2019
San Diego, CA
More events....

DECEMBER 2018 DIGITAL EDITION

BIOPHARMA MANUFACTURING EBOOK

2018 CMO & CRO AWARDS EDITIONS

   

@LIFESCILEADER1